Impact of Prematurity on Nutrient Signaling and Protein Synthesis in Skeletal Muscle

Antonio C Ramos Dos Santos1, Ki Beom Jang2, Marta L Fiorotto3

  • 1Institute for Advancing Health Through Agriculture, Texas A&M AgriLife Research, College Station, Texas, USA ;

Insights

Preterm birth impairs muscle growth by disrupting nutrient signaling pathways like mTORC1. Nutritional strategies mimicking natural feeding patterns can help restore muscle protein synthesis in preterm infants.

Area of Science:

  • Biochemistry
  • Physiology
  • Neonatology

Background:

  • Preterm birth significantly impacts skeletal muscle development and long-term metabolic health.
  • Infants born preterm frequently exhibit postnatal growth failure, characterized by inadequate lean mass.
  • Nutrient-responsive signaling pathways are crucial for muscle growth but are disrupted by prematurity.

Purpose of the Study:

  • To review how prematurity affects insulin and amino acid signaling to mTORC1, a key regulator of protein synthesis.
  • To explore the molecular mechanisms underlying impaired muscle growth in preterm infants.
  • To identify potential nutritional interventions for improving muscle anabolism.

Main Methods:

  • Review of translational research models investigating signaling pathways in preterm infants.
  • Analysis of insulin and amino acid signaling pathways, including mTORC1, PDK1/mTORC2-Akt, and leucine sensing.
  • Examination of evidence regarding the impact of feeding strategies on anabolic signaling.

Main Results:

  • Prematurity intrinsically blunts the activation of mTORC1 and its downstream targets, irrespective of birth weight or comorbidities.
  • Defects in insulin signaling (via PDK1/mTORC2-Akt) and amino acid sensing impair mTORC1-dependent translation initiation.
  • Reduced muscle protein synthesis is a direct consequence of these signaling defects.

Conclusions:

  • Understanding the molecular basis of impaired muscle growth in preterm infants is essential for developing targeted interventions.
  • Nutritional strategies that promote physiological nutrient pulsatility, such as bolus feeding or pulsatile leucine supplementation, show potential for restoring anabolic signaling.
  • Improving muscle growth in preterm infants can mitigate long-term metabolic health risks.

Related Concept Videos

Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Formation of Muscle Fibers from Myoblasts01:13

Formation of Muscle Fibers from Myoblasts

De novo myogenesis, or the formation of muscle fibers, begins during the early embryonic stages. The skeletal muscle is formed from somites– blocks of embryonic cell layers. The somites are further divided into dermatomes, myotomes, sclerotomes, and syndetomes. Among these, the myotomes give rise to muscle fibers.
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription factors...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...